PHAXIAM Therapeutics (XPAR:PHXM) COGS-to-Revenue : 0.00 (As of Sep. 2023)

View and export this data going back to 2013. Start your Free Trial

What is PHAXIAM Therapeutics COGS-to-Revenue?

PHAXIAM Therapeutics's Cost of Goods Sold for the three months ended in Sep. 2023 was €0.00 Mil. Its Revenue for the three months ended in Sep. 2023 was €0.00 Mil.

PHAXIAM Therapeutics's COGS to Revenue for the three months ended in Sep. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. PHAXIAM Therapeutics's Gross Margin % for the three months ended in Sep. 2023 was N/A%.

PHAXIAM Therapeutics COGS-to-Revenue Historical Data

The historical data trend for PHAXIAM Therapeutics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PHAXIAM Therapeutics COGS-to-Revenue Chart

PHAXIAM Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

COGS-to-Revenue

Get a 7-Day Free Trial

PHAXIAM Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

PHAXIAM Therapeutics COGS-to-Revenue Calculation

PHAXIAM Therapeutics's COGS to Revenue for the fiscal year that ended in Dec. 2022 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

PHAXIAM Therapeutics's COGS to Revenue for the quarter that ended in Sep. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

PHAXIAM Therapeutics (XPAR:PHXM) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

PHAXIAM Therapeutics's Gross Margin % for the three months ended in Sep. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

PHAXIAM Therapeutics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of PHAXIAM Therapeutics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

PHAXIAM Therapeutics (XPAR:PHXM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PHAXIAM Therapeutics SA (XPAR:PHXM) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

PHXM:USA 2E41:Germany

Address

60 Avenue Rockefeller, Lyon, FRA, 69008

Website

https://www.erytech.com

Erytech Pharma SA is a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases. Its ERYCAPS platform, uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its lead product candidate eryaspase, also referred as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing eryaspase for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple negative breast cancer, or TNBC.